Tumor necrosis factor receptor: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
== Function == | == Function == | ||
'''Tumor necrosis factor receptor''' (TNFR) or '''death receptor''' is a trimeric cytokine receptor which binds TNF<ref>PMID:10358762</ref>. TNFR family contains several members and superfamily (TNFRSF) members. <br /> | '''Tumor necrosis factor receptor''' (TNFR) or '''death receptor''' is a trimeric cytokine receptor which binds TNF<ref>PMID:10358762</ref>. TNFR family contains several members and superfamily ('''TNFRSF''') members. <br /> | ||
* '''TNFRSF 1''' is called '''Lymphotoxin-α or TNF-β'''<ref>PMID:20566898</ref>;<br /> | * '''TNFRSF 1''' is called '''Lymphotoxin-α or TNF-β'''<ref>PMID:20566898</ref>;<br /> | ||
* '''TNFRSF 3''' is called '''TNFR-III''';<br /> | * '''TNFRSF 3''' is called '''TNFR-III''';<br /> |
Latest revision as of 11:53, 20 August 2024
FunctionTumor necrosis factor receptor (TNFR) or death receptor is a trimeric cytokine receptor which binds TNF[1]. TNFR family contains several members and superfamily (TNFRSF) members.
See also RelevanceTRAPS - a condition characterized by recurrent episodes of fever is associated with TNFR[3]. Structural highlightsThe extracellular domain of TNFR contains 2 to 6 cysteine-rich domains (CRD). The . The CRDs are involved in binding of TNF[4]. . Water molecules are shown as red spheres. 3D structures of tumor necrosis factor receptorTumor necrosis factor receptor 3D structures
|
|
ReferencesReferences
- ↑ Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-67. PMID:10358762 doi:http://dx.doi.org/10.1146/annurev.immunol.17.1.331
- ↑ Mounzer RH, Svendsen OS, Baluk P, Bergman CM, Padera TP, Wiig H, Jain RK, McDonald DM, Ruddle NH. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood. 2010 Sep 23;116(12):2173-82. PMID:20566898 doi:10.1182/blood-2009-12-256065
- ↑ Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi: 10.1007/s10067-014-2556-8. Epub 2014, Mar 11. PMID:24609716 doi:http://dx.doi.org/10.1007/s10067-014-2556-8
- ↑ Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996 Nov 15;4(11):1251-62. PMID:8939750